Funding

SECTION I: ESTIMATION OF COSTS

 

1

Taking into account the rest of the cost evaluation please provide an overall estimation of the total costs for full deployment/production of the R & D result.
… in terms of IPR protection
License file application 700 euros, maintenance 350 euros/year
…in terms of product development
Testing equipment: 60.000

Testing engineer: 60.000

Bioref test lab: 120.000

…in terms of mass production
There are no mass production costs
… in terms of marketing
Marketing will start after the first year of development. In the second year will be allocated 20.000 euro and the next years the marketing cost will follow a steady plan 10.000 per year.

 

 

 

 

 

 

 

 

 

 

 

 

2

Based on the above assessment as well as the marketing information please provide the correct estimation of the price for R&D product in correlation with costs

 

Year 1

Year 2

Year 3

Year 4

Year 5

 
Fixed costs

40,000

50,000

60,000

70,000

80,000

 
Personnel

60,000

30,000

35,000

40,000

50,000

 
Other running costs

180,000

12,000

14,000

16,000

18,000

 
Marketing costs

0

20,000

10,000

10,000

10,000

 
TOTAL EXPECTED COSTS

280,000

112,000

119,000

136,000

158,000

 
Price per Unit

35000

35000

35000

35000

35000

 
Number of Units

0

3

9

12

16

 
TOTAL Expected Revenues

0

105,000

315,000

420,000

560,000

 
CASH FLOW REQUIRED (REVENUES-COSTS)

-280,000

-7,000

196,000

284,000

402,000

 
TOTAL CAPITAL required for five years 287.000 to cover the first two years of operations and 50.000 euro for running costs. Total 337.000  

 

SECTION 2: QUALITATIVE FACTORS

 

3

Dimension of identified target groups
The identified target group for industrial Bioref designs assumes a price 35000 euro per industrial design. The firs year is allocated for development of the Bioref lab. The market is wide (farmers, agricultural associations) but the target goal is moderate considering the fact that Bioref is a new Technology.

 

4

Evaluation of financial Risks for R&D result
The financial risk are described in terms of emerging competitive technologies that are possible to emerge in the first year of development. Since there is a competitive research environment time to market is an important success factor.

SECTION 3: IDENTIFICATION OF FINANCING SOURCES

After evaluating all the above mentioned criteria, please tick the best financing source for the achievement of R&D result (i.e. own capitals, banking credits, venture capital, business angels, etc)

 

1. European Funding

Define relevance of the product with the following potential funding sources and comment

FP7 Energy

Intelligent energy

 

2. National Funding
Low availability of research programmes at national level.

 

3. Private funding
Venture capitals, joint ventures with private funding from large web service providers

 

4. Other
 

SECTION 3: FINAL EVALUATION

It is requested a final evaluation considering the funding opportunities you believe most suitable for the exploitation of the R&D result, considering the possibility of the creation of a spin-off, further research, in particular, a cost/benefit analysis and a financial projection for the R&D result, type of collaboration identified (i.e. Licensing Agreement, Technical Cooperation, Joint Venture, Manufacturing Agreement, Commercial Agreement with Technical Assistance, Creation of a spin-off, Joint further development)…
The recommended funding scheme is joint venture with the manufacturers tat could take up bioref prototype in to industrial production. The joint venture assumes common share and agreement on IPR and agreement on industrial design capitalization.

Decision of evaluation (Please keep only the appropriate)

The R&D has a high potential.

 

Bookmark the permalink. Follow any comments here with the RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

Post a Comment

You must be logged in to post a comment.

Request a proposal

Valorisation Plan Authors

Related Documents

There in no related documents

Visit the other applications of the INTERVALUE Platform: R&D Repository | IP Agreements

© 2009-2010 INTERVALUE Project